Tamoxifen and mammographic breast densities.
暂无分享,去创建一个
J. Brisson | E. Maunsell | J. Robert | E Maunsell | J Brisson | B Brisson | G Coté | S Bérubé | J Robert | G. Côté | S. Bérubé | B. Brisson | G. Côté
[1] M A Astrahan,et al. The detection of changes in mammographic densities. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[2] A. Morrison,et al. Height and weight, mammographic features of breast tissue, and breast cancer risk. , 1984, American journal of epidemiology.
[3] David J Hunter,et al. Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.
[4] A. Morrison,et al. Diet, mammographic features of breast tissue, and breast cancer risk. , 1989, American journal of epidemiology.
[5] N. Boyd,et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group. , 1997, Journal of the National Cancer Institute.
[6] N F Boyd,et al. Automated analysis of mammographic densities and breast carcinoma risk , 1997, Cancer.
[7] M. Gail,et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.
[8] M. Pike,et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. , 1993, Epidemiologic reviews.
[9] R N Hoover,et al. Mammographic densities and risk of breast cancer , 1991, Cancer.
[10] D. Le Roith,et al. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. , 1997 .
[11] U. Veronesi,et al. Mammographic patterns in breast cancer chemoprevention with fenretinide (4-HPR). , 1993, European journal of cancer.
[12] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[13] L. Bernstein,et al. Endogenous hormones and breast cancer risk. , 1993, Epidemiologic reviews.
[14] V. Jordan. Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. , 1998, Journal of the National Cancer Institute.
[15] N. Boyd,et al. Mammographic densities and breast cancer risk. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[16] J. Wolfe,et al. Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: a case-control study. , 1987, AJR. American journal of roentgenology.
[17] E. Fishell,et al. Radio-free America: what to do with the waste. , 1994, Environmental health perspectives.
[18] S. Cummings,et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.
[19] A. Morrison,et al. Mammographic parenchymal features and breast cancer in the breast cancer detection demonstration project. , 1988, Journal of the National Cancer Institute.
[20] N. Boyd,et al. Relationship between mammographic and histological risk factors for breast cancer. , 1992, Journal of the National Cancer Institute.
[21] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[22] T. Powles,et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.
[23] P. Boyle,et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.
[24] F Merletti,et al. Mammographic features of the breast and breast cancer risk. , 1982, American journal of epidemiology.
[25] A. Engeland,et al. Prostate cancer--look to Denmark? , 1996, Journal of the National Cancer Institute.
[26] A. Miller,et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. , 1995, Journal of the National Cancer Institute.
[27] M. Pike,et al. Can mammographic densities predict effects of tamoxifen on the breast? , 1996, Journal of the National Cancer Institute.
[28] W. Willett,et al. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. , 2000, Cancer research.
[29] J. Wolfe,et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. , 1995, Journal of the National Cancer Institute.
[30] C. Redmond,et al. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. , 1990, Journal of the National Cancer Institute.
[31] J. Wolfe. Breast patterns as an index of risk for developing breast cancer. , 1976, AJR. American journal of roentgenology.
[32] M. Pike,et al. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. , 1994, Journal of the National Cancer Institute.
[33] J. Wolfe. Risk for breast cancer development determined by mammographic parenchymal pattern , 1976, Cancer.